CWA
ATYR

Clearview Wealth Advisors’s aTyr Pharma ATYR Stock Holding History

Clearview Wealth Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$1.08K – 678
2023
Q2 		$1.08K Hold
500
– – ﹤0.01% 597
2023
Q1 		$1.05K Buy
+500
New +$1.1K ﹤0.01% 577

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Clearview Wealth Advisors's ATYR Position: Q3 2023 in Review

Clearview Wealth Advisors sold out of aTyr Pharma (ATYR) in Q3 2023, closing a stake of 500 shares — an estimated $1.08K sold.

Clearview Wealth Advisors first reported a position in ATYR in Q1 2023 and held it in 2 quarters. The position peaked at $1.08K in Q2 2023. 40 funds tracked by Wall St. Rank hold ATYR as of Q3 2023.

  • Clearview Wealth Advisors reported no remaining aTyr Pharma position as of Q3 2023 after selling out during the quarter.
  • Clearview Wealth Advisors sold 500 aTyr Pharma shares in Q3 2023, an estimated $1.08K.
  • Clearview Wealth Advisors first reported a position in aTyr Pharma in Q1 2023 and held it in 2 quarters.
  • Clearview Wealth Advisors's aTyr Pharma position peaked at $1.08K in Q2 2023.
  • 40 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2023.

Based on Clearview Wealth Advisors's 13F filing for Q3 2023, filed 30 Oct 2023.